Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101).
Roberto Carmagnani PestanaJustin Tyler MoyersJason RoszikShiraj SenDavid S HongAung NaingCynthia E HerzogSiqing FuSarina A Piha-PaulJordi Rodon AhnertTimothy Anthony YapDaniel D KarpApostolia-Maria TsimberidouShubham PantMaria Alejandra ZarzourRavin RatanVinod RaviRobert S BenjaminAlexander J F LazarWei-Lien WangNajat C DawJonathan D GillDouglas J HarrisonValerae O LewisChristina Lynn RolandShreyaskumar R PatelJonathan A LivingstonNeeta SomaiahJoseph A LudwigAnthony P ConleyNelson HammerschlakRichard G GorlickFunda Meric-BernstamVivek SubbiahPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
Enrollment in biomarker-matched early-phase trials is associated with improved outcomes in heavily pretreated patients with metastatic sarcoma. Molecular testing of tumors from patients with advanced sarcoma and enrollment in matched trials is a reasonable therapeutic strategy.